Tales of the Unexpected: Tcf1 Functions as a Tumor Suppressor for Leukemias  by Staal, Frank J.T. & Clevers, Hans
Immunity
Previewsexpression (Figure 1). However, what
remains unclear is how chronic or strong
TCR signaling causes the demethylation
of such a specific set of genes. Is a certain
threshold of TCR-signal strength or dura-
tion sufficient for inducing demethylation?
Are all the players downstream of the
TCR, or do other cell-extrinsic signals
contribute? Given that chronic in vitro
stimulation could not fully induce nTreg
cell demethylation, the authors suggest
that additional signals might be required
for demethylation of the Foxp3 locus.
Given the importance of IL-2 and TGF-b
in Treg cell function, it would be impor-
tant to interrogate the roles of these
cytokines and other signals in mediating
nTreg-Me. Furthermore, the developmentof novel biomarkers and/or noninvasive
approaches to visualizing nTreg-Me is
critical for further mechanistic dissection
and clinical application.REFERENCES
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The Wnt-responsive transcription factors Tcf1 and Lef1 are well-known for their roles in lymphocyte devel-
opment. In this issue of Immunity, Yu et al. (2012) report that Tcf1-deficient mice develop aggressive T cell
lymphomas that are characterized by high Lef1 expression.A large body of evidence has shown that
canonical Wnt signaling is essential for
thymocyte proliferation and T cell devel-
opment (reviewed in Staal et al. [2008]).
The nuclear response to Wnt signaling
is mediated via a family of four transcrip-
tion factors, Tcf1, Lef1, Tcf3, and Tcf4,
that utilize their HMG (high-mobility-
group) box for sequence-specific DNA
binding. In blood and immune cells,
Tcf1 (T cell factor 1) and Lef1 (lympho-
cyte enhancer-binding factor 1) are
most abundantly expressed. Wnt pro-
teins function during development in
cell fate decisions. In adult life, they
regulate self-renewal of various types
of stem cells, including hematopoietic
stem cells (Clevers, 2006; Luis et al.,
2012). At least three different Wnt path-ways are currently recognized: the
canonical Wnt pathway, which is medi-
ated via b-catenin and Tcf and/or Lef
factors, the planar cell polarity (PCP)
pathway, and the Wnt-Ca2+ pathway
(Staal et al., 2008). In the canonical Wnt
pathway, Wnt proteins bind to their
receptors, thereby preventing proteoso-
mal degradation of the Wnt mediator
b-catenin. Subsequently, b-catenin is
translocated to the nucleus where it
forms an active transcription complex
with the downstream effectors of the
Tcf family. Tcf1 and Lef1 are highly
similar in structure and amino acid
sequence. Both occur as long isoforms
containing a b-catenin-interaction do-
main as well as short isoforms that lack
this domain and function as naturalrepressors of Wnt signaling. The long
isoforms can also function as tran-
scriptional repressors in the absence of
b-catenin when these domains are occu-
pied by Groucho corepressor proteins.
The first reports on Wnt signaling in the
immune system were foreshadowed by
‘‘old’’ experiments demonstrating defects
in T- and B-cell development in mice
deficient for Tcf1 and Lef1, respectively
(reviewed in Staal et al. [2008]). Young
Tcf1-deficient mice display an incomplete
block at the double negative-1 (DN1),
DN2 and immature single positive (SP)
stages of thymocyte development,
whereas older mice have a complete
block at the DN1 stage (see Figure 1,
top, for a description of developmental
stages in the mouse thymus and howovember 16, 2012 ª2012 Elsevier Inc. 761
Figure 1. Dual Role for Tcf1 in the Thymus
The top panel depicts the stages of development as commonly discerned in the mouse thymus. Early
thymic progenitors (ETP) undergo Notch signaling to become committed T lineage cells and transverse
through CD4CD8 double-negative stages (DN) in which Tcrb rearrangements occur at the DN3 stage,
followed by a proliferative stage in which CD8 is expressed in absence of a full T cell receptor (TCR),
referred to as immature single positive (ISP), prior to becoming CD4+CD8+ (double positive) thymocytes
that undergo positive and negative selection to become either CD4 or CD8 single positive thymocytes.
The partial arrests in T cell development at DN1, DN2, DN3, and ISP, in Tcf7/ mice become full
blocks at DN3 or ISP when Lef1 also is deficient. This indicates a cooperative redundant function of
Tcf1 and Lef1. Surprisingly, Tcf7/mice also develop T cell lymphomas of several different phenotypes,
all characterized by high expression of Lef1. This indicates that Tcf1 represses Lef1 to inhibit cellular
transformation, indicating antagonistic roles of Tcf1 and Lef1.
The bottom panel shows that at least three Tcf binding sites upstream of the Lef1 coding sequence
mediate repression of Lef1 in the normal wild-type situation, either via Wnt-b-catenin (Yu et al., 2012) or
by dominant-negative Tcf1 isoforms (Tiemessen et al., 2012). Deficiency in Tcf1 leads to derepression
and much higher Lef1 expression, as seen in Tcf1-defcient T cell lymphomas.
Immunity
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Although Lef1–/– mice display normal
T cell development, mice deficient in
Lef1 and hypomorphic for Tcf7 (the gene
encoding Tcf1) show a complete block
in T cell differentiation at the immature
SP stage, revealing redundancy between
these factors during thymocyte develop-
ment. The finding that Tcf1 and Lef1
interact with the Wnt mediator b-catenin
fits well with the notion that canonical
Wnt signaling provides crucial prolifera-
tive signals to immature T and B cells.
Two similar papers now independently
report that Tcf1-deficient mice surpris-
ingly develop thymic T cell lymphomas,
the mouse equivalent of human T-acute
lymphoblastic leukemia (T-ALL). In the
current issue of Immunity, Yu et al. report
the occurrence of clonal T cell lymphomas
in these mice (Yu et al., 2012). These
findings echo the description of Tcf1 as
a tumor suppressor in the gut, where
Wnt signaling also is required for stem762 Immunity 37, November 16, 2012 ª2012cell maintenance (Roose et al., 1999).
The lymphomas arose at a median age
of 30 weeks and expressed more Lef1
and Id2 messenger RNA (mRNA) (known
Wnt target genes in other cell types) than
normal thymocytes and often coex-
pressed Notch target genes, such as
Hes1, Dtx1, and Ptcra. The authors also
show that although Notch1 somatic
mutations do occur in the lymphomas,
this is not a prerequisite for lymphoma-
genesis. This notion is important, because
in many (>50%) human T-ALL cases,
Notch1 mutations represent initiating
oncogenic events. Authors describe
phenotypic heterogeneity of their tumors,
characterizing them as DN3, DN4, or DP.
Tiemessen and coworkers (Tiemessen
et al., 2012) also demonstrate clonal
aggressive T cell lymphomas character-
ized by high Lef1 mRNA expression and
frequent somatic Notch1 mutations.
Indeed, the Notch1 mutations were not
required for the lymphomas to developElsevier Inc.but more likely support the development
of frank lymphoma. Both groups show
the Lef1 dependency of these lym-
phomas, either by transfecting a domi-
nant-negative form of Lef1 into lymphoma
cells or by genetically removing Lef1
using LoxP-Cre genetic tools.
There are many similarities between
the two studies, and they are fully con-
cordant in their conclusion that Tcf7
functions as a tumor suppressor gene
by repressing the expression of Lef1.
Yet, there is one striking difference that
reflects on the molecular mechanisms
responsible for lymphoma development.
The DN3 lymphomas as described by
Yu et al. (2012) apparently arose inde-
pendently of b-catenin-Wnt signaling
and may be due to Wnt-independent
transcriptional targets regulated by
Lef1, whereas Tiemessen et al. (2012)
describe that most lymphomas are char-
acterized by high expression of the
generic Wnt target gene Axin2. Indeed,
crossing an Axin2-LacZ reporter mouse
with the Tcf7/ mice demonstrates
higher than normal Wnt signaling in most
tumors.
Yu et al. (2012) suggest that Tcf-b-cate-
nin would lead to transcriptional repres-
sion of Lef1 and another Wnt target gene
Id2. Both Lef1 and Id2 are well-known
canonical Wnt target genes in many non-
lymphoid cell types (http://www.stanford.
edu/group/nusselab/cgi-bin/wnt/target_
genes), where they are upregulated by
TCF-b-catenin. In thymocytes, these
Wnt target genes would paradoxically
be repressed rather than activated by
Tcf-b-catenin. Of note, high Wnt activity
leads toWnt-dosage dependent develop-
mental arrest (Luis et al., 2011) and can
lead to T cell lymphomas, as seen in
mice overexpressing stabilized b-catenin
in the thymus (Guo et al., 2007).
The reasons for this difference in Wnt
expression between the lymphomas of
the two reports is not directly obvious.
This may result from a focus on DN3
lymphomas versus all types of lym-
phomas, from different generations of
backcrossing to C57BL/6 (which may
result in phenotypically different arrests
in development), or from the in vivo
Wnt reporters used. Of course, it also
is possible that both b-catenin-depen-
dent and -independent transcriptional
activity of Lef1 contribute to the
lymphomagenesis.
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PreviewsThe current findings in the mouse
appear relevant for human T-ALL. The
(partial) loss of Tcf1 is now also reported
in a subset of pediatric T-ALL, the ETP
group, in which deletions of TCF7 were
found in two patients (Yu et al., 2012).
MEF2C has recently been shown to act
as the master transcriptional regulator of
genes that constitute the signature of
ETP-ALL (Homminga et al., 2011). Inter-
estingly, gene expression profiling of
Tcf7/ lymphomas shows upregulated
expression of Mef2c(Tiemessen et al.,
2012), further supporting the possibility
that lack of Tcf1 may be involved in
development of certain ETP-ALL cases.
The unexpected finding that Tcf1 is
a tumor suppressor gene also indicates
that Tcf1 and Lef1 are not merely redun-
dant in the thymus. For normal T cell
development, a deficiency in both Lef1
and Tcf1 results in a more profound
arrest in thymocyte differentiation than
seen with Tcf1 alone (Yu et al., 2012), indi-
cating a redundant role of these two
factors. However, for the development of
T cell lymphomas, Lef1 is the culprit
leading to cellular transformation,
whereas Tcf1 can function as transcrip-
tional repressor of Lef1, in the role of
a classical tumor suppressor gene. How
this dichotomous cooperative althoughantagonistic relationship between these
two DNA-binding factors is regulated
and if Wnt signaling plays a role in this
regulation is currently not understood
(Figure 1, bottom).
Tcf1 has been shown to act as
commitment factor for the T cell lineage
in hematopoietic stem cells in gain-of-
function experiments (Weber et al.,
2011), a finding that was not corrobo-
rated by the loss-of-function experiments
reported by Yu et al. (2012). This may
indicate that yet another Tcf related
factor, for instance Tcf4, can partially
compensate for loss of both Tcf1 and
Lef1, because inhibition of canonical
Wnt signaling blocks thymopoiesis at
DN1. Whether the dual roles that Tcf1
plays in T cell development are intrinsi-
cally different from the roles of Lef1 or
merely determined by stoichiometry and
abundance of various splice variants
(in different lineages or developmental
stages) remains to be determined.
Nevertheless, the T cell-specific tumor
suppressor function of Tcf1 that is best
known as an activator of the Wnt path-
way is an unexpected twist.REFERENCES
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In this issue of Immunity, Yu et al. (2012) outline a fascinating model in which TLR7-mediated antibody
production acts as a dominant immunosurveillance mechanism against endogenous retroviruses (ERVs),
with additional support of TLR3 and TLR9 that function to prevent ERV-mediated malignancy.Our innate immune system has evolved
several pattern recognition receptors
(PRRs) to sense microbial nucleic
acids. A prominent group of these PRRs
constitutes the subfamily of Toll-like
receptors (TLRs) that has evolved tosense ssRNA and short dsRNA (TLR7,
TLR8), DNA (TLR9), or long dsRNA
(TLR3). Upon ligand recognition, TLR
activation sets off signaling cascades
that are geared toward the eradication
of the microbial pathogen, ranging fromthe activation of immediate effector
functions to the initiation of adaptive
immune responses (Kawai and Akira,
2011).
A large proportion of the mammalian
genome is made up of fossils ofovember 16, 2012 ª2012 Elsevier Inc. 763
